Amolyt Pharma (referred to in the article as Alize Pharma) focuses on creating innovative peptide and protein drugs targeting metabolic disorders and oncology indications. Its lead asset, AZP-531, is an eight-amino-acid unacylated ghrelin analog being advanced for Type II diabetes and Prader-Willi syndrome; the company expects to start Phase I trials in healthy volunteers in 2013, followed by Phase Ib/II studies in patients. A second program, ASPAREC, is a PEGylated recombinant L-asparaginase for acute lymphoblastic leukemia that is already in Phase I and partnered with EUSA Pharma. The firm controls five patent families covering 34 patents and applications around UAG, its analogs, and related uses. Founded in 2007, the company pursues a strategy of bringing assets to early clinical proof-of-concept before licensing to larger pharmaceutical partners. Including the current round, Amolyt/Alize has raised a total of €8.3 million from private and institutional backers to fund its R&D milestones and clinical progression.

Total raised

$303M

Funding rounds

6

Latest round

Series C

Latest activity

Jan 2023